A77 1726 inhibits IL-1β-induced prostaglandin E(PGE) productionin human synovial fibroblasts and articular chondrocytes

<p><b>Copyright information:</b></p><p>Taken from "The active metabolite of leflunomide, A77 1726, increases the production of IL-1 receptor antagonist in human synovial fibroblasts and articular chondrocytes"</p><p>Arthritis Research & Therapy 2004;6(3):R181-R189.</p><p>Published online 19 Feb 2004</p><p>PMCID:PMC416438.</p><p>Copyright © 2004 Palmer et al., licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.</p> Human osteoarthritis (OA) synovial fibroblasts (passage 1), de-differentiated human OA articular chondrocytes (passage 4), and freshly isolated human OA articular chondrocytes were stimulated or not (control; white bars) with 1 ng/ml IL-1β (hatched bars), the combination of 1 ng/ml IL-1β and 100 μmol/l A77 1726 (black bars), or the combination of 1 ng/ml IL-1β and 5 μg/ml indomethacin (grey bars) for 48 hours. A77 1726 or indomethacin was added 2 hours before stimulation with IL-1β. PGEconcentrations in culture supernatants were measured as described elsewhere []. Results are represented as means ± SEM of three determinations in one representative experiment. Similar results were obtained with cells from two different donors (two OA samples) for synovial fibroblasts, three different donors (three OA samples) for de-differentiated chondrocytes and five different donors (three normal and two OA samples) for freshly isolated chondrocytes. *< 0.01 versus control; < 0.01 versus IL-1β.